STOCK TITAN

Oruka Therapeutics' Arjun Agarwal sells 10,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) reported that Senior Vice President, Finance Arjun Agarwal exercised options covering 8,542 and 1,458 common shares at exercise prices of $12.50 and $34.39 per share, respectively, on November 12, 2026. He also sold 10,000 common shares that day in six transactions; the reported weighted-average prices for those sale tranches ranged from $101.9758 to $107.0000 per share. The sales were made under a Rule 10b5-1 trading plan entered into February 11, 2026.

Insider Agarwal Arjun
Role Senior Vice President, Finance
Sold 10,000 shs ($1.05M)
Approx. gross sale proceeds $1.05M
Approx. exercise cost $157K
Approx. pre-tax spread $893K
Share of Position Sold 41.3%
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F7 8,542 $0.00 $0.00
Exercise Employee Stock Option (right to buy) F8 1,458 $0.00 $0.00
Exercise Common Stock 8,542 $12.50 $107K
Exercise Common Stock 1,458 $34.39 $50K
Sale Common Stock F1, F2 500 $101.9758 $51K
Sale Common Stock F1, F3 801 $103.1556 $83K
Sale Common Stock F1, F4 799 $104.2502 $83K
Sale Common Stock F1, F5 6,842 $105.2806 $720K
Sale Common Stock F1, F6 958 $106.1759 $102K
Sale Common Stock F1 100 $107.00 $11K
Holdings After Transaction: Employee Stock Option (right to buy) — 123,251 options (Direct); Common Stock — 14,219 shares (Direct)
Holdings Before and After: Employee Stock Option (right to buy), 133,251 to 123,251 options (Direct); Common Stock, 14,219 to 14,219 shares (Direct)
Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (8)
  1. F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.22, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.75 to $103.70, inclusive.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $104.65, inclusive.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.82 to $105.81, inclusive.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.82 to $106.52, inclusive.
  7. F7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
  8. F8. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Option exercise and common shares acquired 8,542 shares at $12.50 per share November 12, 2026
Option exercise and common shares acquired 1,458 shares at $34.39 per share November 12, 2026
Common shares sold 10,000 shares November 12, 2026; six transactions under a Rule 10b5-1 trading plan
Largest sale tranche 6,842 shares at a weighted-average price of $105.2806 per share November 12, 2026
Rule 10b5-1 trading plan regulatory
"sales were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (right to buy) financial
"Employee Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORKA shares did Arjun Agarwal sell, and at what prices?

Agarwal sold 10,000 ORKA shares on November 12, 2026, in six transactions under a Rule 10b5-1 plan entered into February 11, 2026. The reported weighted-average prices were $101.9758 for 500 shares, $103.1556 for 801, $104.2502 for 799, $105.2806 for 6,842, $106.1759 for 958, and $107.0000 for 100 shares.

How many ORKA shares did Arjun Agarwal acquire through option exercises?

He exercised options to acquire 8,542 common shares at $12.50 per share and 1,458 common shares at $34.39 per share on November 12, 2026.

What were the vesting terms for Arjun Agarwal's exercised ORKA options?

The option covering 8,542 shares vests as to 1/48 of the underlying shares monthly from January 1, 2025. The option covering 1,458 shares vests on the same 1/48 monthly basis from January 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Agarwal Arjun

(Last)(First)(Middle)
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100

(Street)
MENLO PARK CALIFORNIA 94025

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Senior Vice President, Finance
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026M8,542A$12.522,761D
Common Stock11/12/2026M1,458A$34.3924,219D
Common Stock11/12/2026S(1)500D$101.9758(2)23,719D
Common Stock11/12/2026S(1)801D$103.1556(3)22,918D
Common Stock11/12/2026S(1)799D$104.2502(4)22,119D
Common Stock11/12/2026S(1)6,842D$105.2806(5)15,277D
Common Stock11/12/2026S(1)958D$106.1759(6)14,319D
Common Stock11/12/2026S(1)100D$10714,219D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$12.511/12/2026M8,542 (7)01/21/2035Common Stock8,542$067,834D
Employee Stock Option (right to buy)$34.3911/12/2026M1,458 (8)01/22/2036Common Stock1,458$055,417D
Explanation of Responses:
1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.22, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.75 to $103.70, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $104.65, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.82 to $105.81, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.82 to $106.52, inclusive.
7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
8. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading